GRAPPA 2019 Research Recipient Awards Report

References

1. 1.↵
   1. Ritchlin CT,
   2. Colbert RA,
   3. Gladman DD

   . Psoriatic arthritis. N Engl J Med 2017;376:957-70.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Lee AY,
   2. Körner H

   . CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis. Immunol Cell Biol 2014;92:354-8.

   OpenUrlCrossRef
3. 3.↵
   1. Hedrick MN,
   2. Lonsdorf AS,
   3. Hwang ST,
   4. Farber JM

   . CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 2010;14:911-22.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Getschman AE,
   2. Imai Y,
   3. Larsen O,
   4. Peterson FC,
   5. Wu X,
   6. Rosenkilde MM, et al

   . Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model. Proc Natl Acad Sci U S A 2017;114:12460-5.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Adamopoulos IE,
   2. Tessmer M,
   3. Chao CC,
   4. Adda S,
   5. Gorman D,
   6. Petro M, et al

   . IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 2011;187:951-9.

   OpenUrlAbstract/FREE Full Text
6. 3.↵
   1. Leys L,
   2. Wang Y,
   3. Paulsboe S,
   4. Edelmayer R,
   5. Salte K,
   6. Wetter J, et al

   . Characterization of psoriasiform dermatitis induced by systemic injection of interleukin-23 minicircles in mice. J Dermatol 2019;46:482-97.

   OpenUrlCrossRefPubMed